TPM3 and sarcoma: To the best of our knowledge, this is the first case of a spindle cell sarcoma with both TPM3::NTRK1 fusion and MDM2/CDK4 amplification showing a significant response to NTRK inhibitor, suggesting NTRK fusion plays an oncogenic role in this sarcoma.